1. Introduction
===============

Hepatitis B is a common disease worldwide. Approximately, one million human deaths in the world each year are attributable to the end stage sequelae of persistent hepatitis B virus (HBV) infection. The World Health Organization (WHO) has estimated that about 350 million people worldwide are chronically infected with HBV [@B1]. These individuals are prone to the development of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. In South East Asia, the mode of HBV infection is mainly vertical transmission in the perinatal period. In China, one of the major reasons for the high prevalence of HBV infection is that mothers transmit the HBV to their children during the intrauterine as well as perinatal periods. Approximately 50% HBV carriers got infected *via* mother-to-infant transmission [@B1], [@B2], [@B3]. With the immunolization of hepatitis B vaccine and the use of hepatitis B immunoglobulin (HBIG) in hepatitis B surface antigen (HBsAg)-positive pregnant women, the incidence of HBV carrier status among the children has reduced dramatically. However, intrauterine HBV infection still occurs at high incidence. The exact mechanisms underlying intrauterine infection of HBV have not been completely elucidated. Previous studies showed that major histocompatibility complex (MHC) gene products were vital for the regulation of several antiviral immune reactions [@B4], [@B5]. In addition, genetic factors controlling the host immune response could play an important role in determining the infection outcome [@B6], [@B7]. These immune responses may be genetically determined, since studies on twins and families have suggested the contribution of an inherited component in the development of chronic hepatitis B infection [@B8].

T cell responses are restricted by human leukocyte antigen (HLA) class I and class II molecules, which present antigens to CD8+ cytolytic T cells and CD4+ helper T cells, respectively. The genes encoding HLA class I and class II molecules are the most polymorphic genes in the human genome and are therefore ideal candidates for the investigation of HBV infection susceptibility.

The association between HLA polymorphism and disease susceptibility as well as disease resistance has been documented [@B9], [@B10], [@B11]. Recently, several non-genetic diseases were found to be related to gene polymorphism, and the relationship between the TNF-α -238 A and IFN-γ +874 A alleles and intrauterine HBV infection was reported [@B12], [@B13]. It is important to further examine the relationship between intrauterine HBV infection and HLA gene polymorphism.

To study the association between the polymorphisms of HLA class II genes and intrauterine HBV infection, we selected the newborn infants delivered by HBsAg-positive mothers in this study and compared the frequencies of HLA phenotypes between the intrauterine HBV infection infant group and the non-intrauterine HBV infection infant group. To this end, an 1:2 matched nested case-control design was used.

Materials and Methods
=====================

Patients
--------

This study included the patients who visited the Department of Obstetrics and Gynecology at the Maternity and Child Care Centre of ShanXi Province from February 1999 to October 2004. A written consent was obtained from each of the participants. A nested case-control design was used. The patients selected were newborn infants whose blood were tested positive for HBsAg within 24 hr of birth (intrauterine HBV infection group, N = 24). The controls were newborn infants whose blood were tested negative for HBsAg (non-intrauterine HBV infection group, N = 48). Each patient was compared with 2 controls from the same cohort based on factors that were associated with the pregnant women as well as the newborn infants. These factors included age of the newborns (difference was within 6 months); same gender of the newborns, and the HBV marker levels in the maternal serum before delivery.

Specimen Collection
-------------------

Venous blood specimens from pregnant women and femoral vein blood specimens of the newborn infants were collected within 24 hr after birth and stored at --20°C for laboratory testing. After blood collection, the newborn infants immediately received hepatitis B immune globulin (HBIG) intramuscularly. They were also administered with hepatitis B vaccines at month 0, 1, and 6.

Criteria for Intrauterine HBV Infection
---------------------------------------

Newborn infants whose venous blood specimens were collected within 24 hr after birth, if found positive for HBsAg and/or HBV DNA, were considered HBV infected intrauterinely. In order to exclude the possibility that the intrauterine infection was tested positive due to transplacental maternal contamination of the fetal circulation, we followed up all of the patients for at least 6 months.

Determination of HBsAg and HBeAg in Serum
-----------------------------------------

The presence of serum HBsAg and HBeAg was tested by ELISA (Shanghai Ke-hua Biotechnology Company, Shanghai, China). The results were generated using a Multiskan MK3 ELISA detector. A positive/negative (P/N) ratio ≥ 2.1 was considered positive.

Extraction of Genomic DNA
-------------------------

The genomic DNA of the newborns was extracted from peripheral blood mononuclear cells by using the QIAamp blood kit (QIAGEN Inc., Chatsworth, CA) according to the manufacturer\'s instructions.

HLA class II Typing
-------------------

HLA class II alleles were typed using the low-resolution DNA typing method----a polymerase chain reaction-sequence specific primer (PCR-SSP) technique (Pel-Freez, Brown Deer, WI) according to the manufacturer\'s instructions. Gene typing was performed using the software supplied by the company.

Statistical analysis
--------------------

Statistical analysis was performed using the SPSS11.0 package software (SPSS Inc., Chicago, IL) on a computer. The frequency of HLA class II alleles was calculated by direct counting. Odds ratios (OR) reflect the likelihood of a specific allele being present in a subject who has intrauterine infection. *P* values were calculated by using conditional logistic regression. Statistic significance was tested by the chi-square test and Fisher\'s exact test. *P*\< 0.05 was considered statistically significant.

Results
=======

Patient characteristics
-----------------------

A total of 312 HBsAg-positive pregnant women delivered 313 newborn infants from February 1999 to October 2004 in the Department of Obstetrics and Gynecology at the Maternity and Child Care Centre of ShanXi Province. There were twins among these newborn infants. Among the 313 newborns, a total of 24 fulfilled our criteria for intrauterine HBV infection, and the infection rate was 7.7% (24/313). There was a significant difference in the maternal serum HBeAg rate (χ^2^*=*19.50, *P\<*0.0001) and the newborn serum HBeAg rate (χ^2^*=*17.62, *P\<*0.0001) between the intrauterine HBV infection and non-intrauterine HBV infection groups. These results indicate that maternal HBeAg-positive serum was a risk factor for intrauterine HBV infection, and the OR was 5.95 (Table [1](#T1){ref-type="table"}). In addition, newborn HBeAg-positive serum was also a risk factor with an OR of 5.39 (Table [1](#T1){ref-type="table"}).

There was no statistically significant difference (*P*\> 0.05) between the infected infants and controls with respect to the mean age and occupation of the mothers, nor the birth weight and gender of the newborn infants.

Distribution of HLA-DR type in the intrauterine infection and non-intrauterine infection groups
-----------------------------------------------------------------------------------------------

In all the newborn infants, DRB3\* was the most frequent HLA-DR type. Its frequency was 37.5% in the intrauterine infection group and 29.17% in the non-intrauterine infection group (Table [2](#T2){ref-type="table"}). In the intrauterine infection group, DRB1\*07 and DRB3\* were the most frequent HLA-DR type (both were 37.5%) in newborn infants, followed by DRB1\*08 (20.83%). In the non-intrauterine infection group, DRB3\* was the most frequent HLA-DR type (29.17%), followed by DRB1\*12 (18.75%) (Table [2](#T2){ref-type="table"}).

Comparison of the frequency of the HLA-DR type between the intrauterine infection and non-intrauterine infection groups
-----------------------------------------------------------------------------------------------------------------------

There was a significant difference in the distribution of HLA-DRB1\*07 between the intrauterine infection and non-intrauterine infection groups. HLA-DRB1\*07 was significantly more frequent in the intrauterine infection group (9 of 24 subjects, 37.5%) as compared to its frequency in the non-intrauterine infection group (4 of 48 subjects, 8.33%) (OR = 6.66, *P =*0.004) (Table [3](#T3){ref-type="table"}). The same analysis did not yield evidence supporting the significant (p\<0.05) involvement of other HLA-DR types as determinants of intrauterine infection (Table [3](#T3){ref-type="table"}).

Discussion
==========

The susceptibility of HBV infection and the immune response to HBsAg-derived vaccines are determined by the genetic background of the host [@B14], [@B15]. Other outcomes, including progression to cirrhosis and/or liver cancer, may also be influenced by host genetics. Thus far, the results of studies on host susceptibility to HBV infection are not conclusive. From the viewpoint of epidemiology, the major problem is the lack of appropriate subjects and suitable research design. In general, in order to conduct such studies, all subjects should be exposed to HBV. In addition, the time and mode of exposure to HBV should be comparable. Then, the difference in the distribution/frequencies of HLA types can be compared between HBV-infected persons and non-infected controls. Unfortunately, such study designs can hardly be realized if our epidemiological survey is based on the common human population. This is because: (1) It is difficult to determine the precise time of HBV exposure and to conduct follow-ups in common human population; (2) Theoretically, we would first require an isolated population from which our subjects can be selected. From this isolated population, the susceptible population should be screened, and subsequently, the infection status of this population should be followed up. However, this is extremely difficult to achieve. Fortunately, intrauterine HBV infection can be studied in newborn infants who are suitable study subjects. Because the newborn infants we studied were all delivered by HBsAg-positive mothers, they were all susceptible to HBV, and their mothers were the only source of HBV infection. These conditions well satisfies our research design requirements.

HLA is involved in immune response to HBV. Although the relationship between various clinical manifestations and polymorphic HLA genes have been the subject of several studies, a definitive relationship has not yet been identified due to the inconsistencies of the results [@B4], [@B16], [@B17], [@B18]. While the mechanism of susceptibility to HBV infection is not well clarified, it is known to be influenced by host immunogenetic factors [@B19], [@B20].

Our results show that maternal HBeAg-positive serum and newborn HBeAg-positive serum were risk factors for intrauterine HBV infection. Several reports indicated that the likelihood of developing chronic HBV infection is higher in newborn infants, whose immune systems are thought to be immature, compared with the immunocompetent subjects during adulthood [@B14], [@B23]. The natural course of chronic HBV infection can be divided into four phases based on the virus-host interaction: immune tolerance, immune clearance, low or non-replication, and reactivation. Most carries with intrauterine HBV infection are present in the immunotolerant phase. These carries are HBeAg positive but with normal alanine aminotransferase (ALT).

Our study has indicated that HLA-DRB1\*07(HLA-DR7) type is associated with HBV intrauterine infection in Chinese people. It is noticeable that in this study the newborn infants with non-intrauterine HBV infection were selected as the controls, which ensured a similar exposure to HBV between the case and control groups. Our results imply that susceptibility to persistent infection is significantly associated with the presence of HLA-DR7 type. Almarri et al [@B21] failed to identify an association between HLA class I and chronic HBV infection. However, they discovered a significant decrease in the frequency of HLA-DR2 and an excess of HLA-DR7 in cases of chronic, persistent HBV infection. HLA-DRB1\*1301/2 has been associated with viral clearance, but HLA-DRB1\*07(HLA-DR7) is associated with non-responsiveness to vaccination with envelope proteins [@B4], [@B22]. It is possible that high expression of HLA-DR7 on the cell surface may restrict the ability of helper T-lymphocytes to recognize HBsAg and B-cells and thereby result in persistent infection. Alternatively, HLA-DR7 may present viral peptides to a specific subset of CD4+ T cells and therefore alt the subsequent immune responses. Nevertheless, compared with our study, those studies did not show the role of HLA-DRB1\*07(HLA-DR7) in HBV intrauterine infection.

To the best of our knowledge, this is the first report involving the study on the association between HLA phenotypes and the outcomes of intrauterine HBV infection in newborn infants. Our data have showed that high frequency of specific HLA phenotypes, such as DRB1\*07, is associated with the susceptibility to HBV intrauterine infection. Thus, our findings support the conclusion that genetic factors (e.g., HLA) are associated with the outcomes of intrauterine HBV infection. The characterization of functional significance of this particular HLA molecule in HBV intrauterine infection may provide insight to develop novel prophylactic and therapeutic approaches. Additional study is needed to validate these findings and to further explore the relationship between HBV intrauterine infection and the susceptible gene(s), as well as any other risk factors which may be involved in HBV intrauterine infection. Finally, investigation to elucidate the genetic pathogenesis of HBV intrauterine infection is among the future studies we plan to pursue.
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###### 

Relationship of serum HBeAg in mothers and newborns to intrauterine infection

  Group                         Maternal HBeAg     Newborn infants HBeAg                                                   
  ----------------------------- ------------------ ----------------------- ------------------- -- ----------- ------------ -----
  Intrauterine infection        15(62.5%)          9(37.5%)                24                     13(54.2%)   11(45.8%)    24
  Non-intrau­terine infection   63(21.9%)          225(78.1%)              288                    52(18.0%)   237(82.0%)   289
  Total                         78(24.3%)          234(75.7%)              312                    65(20.8%)   248(79.2%)   313
  χ^2^                          19.50\*                                    17.62\*                                         
  *OR*(95%CI)                   5.95 (2.29-16.8)                           5.39 (2.08-13.99)                               

*\*P \<*0.0001

###### 

Frequencies of HLA-DR types in the intrauterine infection and non-intrauterine infection groups\#

  HLA-DR Allele type   Intrauterine infection group (N=24)           Non-intrauterine infection group (N=48)        
  -------------------- ------------------------------------- ------- ----------------------------------------- ---- -------
  DRB1\*01             2                                     8.33                                              2    4.17
  DRB1\*03             2                                     8.33                                              5    10.42
  DRB1\*04             4                                     16.67                                             3    6.25
  DRB1\*07             9                                     37.5                                              4    8.33
  DRB1\*08             5                                     20.83                                             5    10.42
  DRB1\*09             4                                     16.67                                             4    8.33
  DRB1\*10             3                                     12.5                                              2    4.17
  DRB1\*11             3                                     12.5                                              7    14.58
  DRB1\*12             2                                     8.33                                              9    18.75
  DRB1\*14             1                                     4.17                                              7    14.58
  DRB1\*15             1                                     4.17                                              8    16.67
  DRB1\*16             2                                     8.33                                              3    6.25
  DRB3\*               9                                     37.5                                              14   29.17
  DRB4\*               4                                     16.67                                             5    10.42
  DRB5\*               1                                     4.17                                              3    6.25

\#The allele carrier frequencies are referred to the frequencies of the population, not individuals.

###### 

Comparison of HLA-DR types between the intrauterine infection and non-intrauterine infection groups

  HLA-DR allele   Frequency(%)in Subjects with   OR         95%CI      *P*              
  --------------- ------------------------------ ---------- ---------- ---------------- -----------
  DRB1\*01        8.33                           4.17       2.091      0.276-15.83      0.597
  DRB1\*03        8.33                           10.42      0.782      0.14-4.36        0.571
  DRB1\*04        16.67                          6.25       3.00       0.61-14.67       0.212
  **DRB1\*07**    **37.5**                       **8.33**   **6.66**   **1.77-24.59**   **0.004**
  DRB1\*08        20.83                          10.42      2.26       0.58-8.74        0.285
  DRB1\*09        16.67                          8.33       2.2        0.49-9.69        0.427
  DRB1\*10        12.5                           4.17       3.28       0.51-21.15       0.325
  DRB1\*11        12.5                           14.58      0.83       0.19-3.57        0.81
  DRB1\*12        8.33                           18.75      0.39       0.08-1.98        0.32
  DRB1\*14        4.17                           14.58      0.25       0.29-2.20        0.25
  DRB1\*15        4.17                           16.67      0.21       0.03-1.85        0.26
  DRB1\*16        8.33                           6.25       1.36       0.21-8.76        1.00
  DRB3\*          37.5                           29.17      1.45       0.52-4.10        0.59
  DRB4\*          16.67                          10.42      1.72       0.42-7.10        0.47
  DRB5\*          4.17                           6.25       0.65       0.06-6.62        1.00
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